Recent Advancements in Multimodality Treatment of Gliomas

• DN Louis H Ohgaki , ODWiestleret al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114(2), 97–109 (2007).
   PubMed Web of Science ®Google Scholar
• Claus EB , PMBlack. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER program, 1973–2001.Cancer106(6), 1358–1363 (2006).
   PubMed Web of Science ®Google Scholar
• Berger MS , DeliganisAV, DobbinsJ, KelesGE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas.Cancer74(6), 1784–1791 (1994).
   PubMed Web of Science ®Google Scholar
• AB Karim , DAfra, PCornuet al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research And Treatment of Cancer Study 22845 with the Medical Research Council Study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 316–324 (2002).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ , AfraD, de WitteOet al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490), 985–990 (2005).
   PubMed Web of Science ®Google Scholar
• Pignatti F , van den BentM, CurranDet al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol. 20(8), 2076–2084 (2002).
   PubMed Web of Science ®Google Scholar
• Shaw E , ArusellR, ScheithauerBet al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J. Clin. Oncol. 20(9), 2267–2276 (2002).
   PubMed Web of Science ®Google Scholar
• Karim AB , MaatB, HatlevollRet al. A randomized trial on dose–response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36(3), 549–556 (1996).
   PubMed Web of Science ®Google Scholar
• Kesari S , DSchiff, JDrappatzet al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin. Cancer Res. 15(1), 330–337 (2009).
   PubMed Web of Science ®Google Scholar
• Pouratian N , GascoJ, ShermanJH, ShaffreyME, SchiffD. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.J. Neurooncol.82(3), 281–288 (2007).
   PubMed Web of Science ®Google Scholar
• Shaw EG , WangM, CoonsSet al. Final report of radiation therapy oncology group protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). Presented at: 2008 ASCO National Meeting. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Scanlon PW , TaylorWF. Radiotherapy of intracranial astrocytomas: analysis of 417 cases treated from 1960 through 1969.Neurosurgery5(3), 301–308 (1979).
   PubMed Web of Science ®Google Scholar
• Fine HA , DearKB, LoefflerJS, BlackPM, CanellosGP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.Cancer71(8), 2585–2597 (1993).
   PubMed Web of Science ®Google Scholar
• Stupp R , MasonWP, van den BentMJet al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Hegi ME , DiserensAC, GorliaTet al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R , HegiME, MasonWPet al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCtrial IC. Lancet Oncol. 10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke JL , IwamotoFM, SulJet al. Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27(23), 3861–3867 (2009).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ , CarpentierAF, BrandesAAet al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized european organisation for research and treatment of cancer Phase I trial II. J. Clin. Oncol. 24(18), 2715–2722 (2006).
   PubMed Web of Science ®Google Scholar
• Cairncross JG , UekiK, ZlatescuMCet al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90(19), 1473–1479 (1998).
   PubMed Web of Science ®Google Scholar
• Cairncross G , BerkeyB, ShawEet al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24(18), 2707–2714 (2006).
   PubMed Web of Science ®Google Scholar
• Smith JS , PerryA, BorellTJet al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18(3), 636–645 (2000).
   PubMed Web of Science ®Google Scholar
• Ino Y , BetenskyRA, ZlatescuMCet al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7(4), 839–845 (2001).
   PubMed Web of Science ®Google Scholar
• Snuderl M , EichlerAF, LigonKLet al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin. Cancer Res. 15(20), 6430–6437 (2009).
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA , BerkeyB, PeereboomDet al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro. Oncol. 11(2), 167–175 (2009).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R . HER1/EGFR targeting: refining the strategy.Oncologist9(1), 58–67 (2004).
   PubMed Web of Science ®Google Scholar
• Rich JN , ReardonDA, PeeryTet al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ , BrandesAA, RamplingRet al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J. Clin. Oncol. 27(8), 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Bianco C , TortoraG, BiancoRet al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (IRESSA). Clin. Cancer Res. 8(10), 3250–3258 (2002).
   PubMed Web of Science ®Google Scholar
• Chakravarti A . An update of Phase II results from RTOG 0211: a Phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. Presented at:2006 ASCO Annual Meeting. Atlanta, GA, USA 2–6 June 2006.
   Google Scholar
• Prados MD , ChangSM, ButowskiNet al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27(4), 579–584 (2009).
   PubMed Web of Science ®Google Scholar
• Peereboom DM , ShepardDR, AhluwaliaMSet al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol. 98(1), 93–99 (2010).
   PubMed Web of Science ®Google Scholar
• Brown PD , KrishnanS, SarkariaJNet al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 26(34), 5603–5609 (2008).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK , WangMY, VivancoIet al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Weller M , FelsbergJ, HartmannCet al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol. 27(34), 5743–5750 (2009).
   PubMed Web of Science ®Google Scholar
• Tabatabai G , StuppR, van den BentMJet al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 120(5), 585–592 (2010).
   PubMed Web of Science ®Google Scholar
• Sampson JH , HeimbergerAB, ArcherGEet al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722–4729 (2010).
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS , GladsonCL. Progress on antiangiogenic therapy for patients with malignant glioma.J. Oncol. 2010:689018 (2010).
   Google Scholar
• Vredenburgh JJ , DesjardinsA, HerndonJE2ndet al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Friedman HS , PradosMD, WenPYet al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Lai A , TranA, NghiemphuPLet al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142–148 (2011).
   PubMed Web of Science ®Google Scholar
• Taga T , SuzukiA, Gonzalez-GomezIet al. α v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer 98(5), 690–697 (2002).
   PubMed Web of Science ®Google Scholar
• Reardon DA , FinkKL, MikkelsenTet al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26(34), 5610–5617 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R , HegiME, NeynsBet al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(16), 2712–2718 (2010).
   PubMed Web of Science ®Google Scholar
• Ishiuchi S , TsuzukiK, YoshidaYet al. Blockage of ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med. 8(9), 971–978 (2002).
   PubMed Web of Science ®Google Scholar
• Grossman SA , YeX, ChamberlainMet al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol. 27(25), 4155–4161 (2009).
   PubMed Web of Science ®Google Scholar
• Yin D , ZhouH, KumagaiTet al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24(3), 344–354 (2005).
   PubMed Web of Science ®Google Scholar
• Kubicek GJ , Werner-WasikM, MachtayMet al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys. 74(2), 433–439 (2009).
   PubMed Web of Science ®Google Scholar
• Nuutinen J , SonninenP, LehikoinenPet al. Radiotherapy treatment planning and long-term follow-up with [(11)c]methionine pet in patients with low-grade astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 48(1), 43–52 (2000).
   PubMed Web of Science ®Google Scholar
• Grosu AL , WeberWA. PET for radiation treatment planning of brain tumours.Radiother. Oncol.96(3), 325–327 (2010).
   PubMed Web of Science ®Google Scholar
• Grosu AL , WeberWA, RiedelEet al. L-(methyl-11c) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63(1), 64–74 (2005).
   PubMed Web of Science ®Google Scholar
• Astner ST , ShiK, VaupelP, MollsM. Imaging of tumor physiology: impacts on clinical radiation oncology.Exp. Oncol.32(3), 149–152 (2010).
   PubMedGoogle Scholar
• Bloom HJ . Combined modality therapy for intracranial tumors.Cancer35(1), 111–120 (1975).
   PubMed Web of Science ®Google Scholar
• Hermanto U , FrijaEK, LiiMJ, ChangEL, MahajanA, WooSY. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain?Int. J. Radiat. Oncol. Biol. Phys.67(4), 1135–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Hall EJ , WuuCS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT.Int. J. Radiat. Oncol. Biol. Phys.56(1), 83–88 (2003).
   PubMed Web of Science ®Google Scholar
• D’Souza WD , RosenII. Nontumor integral dose variation in conventional radiotherapy treatment planning.Med. Phys.30(8), 2065–2071 (2003).
   PubMed Web of Science ®Google Scholar
• Fogh SE , AndrewsDW, GlassJet al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J. Clin. Oncol. 28(18), 3048–3053 (2010).
   PubMed Web of Science ®Google Scholar
• Combs SE , GutweinS, ThilmannC, DebusJ, Schulz-ErtnerD. Reirradiation of recurrent who grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT).Strahlenther. Onkol.181(12), 768–773 (2005).
   PubMed Web of Science ®Google Scholar
• Combs SE , BischofM, WelzelTet al. Radiochemotherapy with temozolomide as reirradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J. Neurooncol. 89(2), 205–210 (2008).
   PubMed Web of Science ®Google Scholar
• Cuneo KC , VredenburghJJ, SampsonJHet al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/j.ijrobp.2010.12.074 (2011) (Epub ahead of print).
   Google Scholar
• Schulz-Ertner D , TsujiiH. Particle radiation therapy using proton and heavier ion beams.J. Clin. Oncol.25(8), 953–964 (2007).
   PubMed Web of Science ®Google Scholar
• Paganetti H , NiemierkoA, AncukiewiczMet al. Relative biological effectiveness (RBE) values for proton beam therapy. Int. J. Radiat. Oncol. Biol. Phys. 53(2), 407–421 (2002).
   PubMed Web of Science ®Google Scholar
• Ando K , KoikeS, OhiraCet al. Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int. J. Radiat. Biol. 75(4), 505–512 (1999).
   PubMed Web of Science ®Google Scholar
• Nakano T , SuzukiY, OhnoTet al. Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin. Cancer Res. 12(7 Pt 1), 2185–2190 (2006).
   PubMed Web of Science ®Google Scholar
• Brada M , Pijls-JohannesmaM, De RuysscherD. Current clinical evidence for proton therapy.Cancer J.15(4), 319–324 (2009).
   PubMed Web of Science ®Google Scholar
• Fitzek MM , ThorntonAF, RabinovJDet al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a Phase II prospective trial. J. Neurosurg. 91(2), 251–260 (1999).
   PubMed Web of Science ®Google Scholar
• Mizumoto M , TsuboiK, IgakiHet al. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 77(1), 98–105 (2010).
   PubMed Web of Science ®Google Scholar
• Fitzek MM , ThorntonAF, HarshGTet al. Dose-escalation with proton/photon irradiation for daumas-duport lower-grade glioma: Results of an institutional Phase I/II trial. Int. J. Radiat. Oncol. Biol. Phys. 51(1), 131–137 (2001).
   PubMed Web of Science ®Google Scholar
• Hug EB , MuenterMW, ArchambeauJOet al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther. Onkol. 178(1), 10–17 (2002).
   PubMed Web of Science ®Google Scholar
• Iwadate Y , MizoeJ, OsakaY, YamauraA, TsujiiH. High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53.Int. J. Radiat. Oncol. Biol. Phys.50(3), 803–808 (2001).
   PubMed Web of Science ®Google Scholar
• Mizoe JE , TsujiiH, HasegawaAet al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined x-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 69(2), 390–396 (2007).
   PubMed Web of Science ®Google Scholar
• Combs SE , BohlJ, ElsasserTet al. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. Int. J. Radiat. Biol. 85(2), 126–137 (2009).
   PubMed Web of Science ®Google Scholar
• Combs SE , KieserM, RiekenSet al. Randomized Phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the cleopatra trial. BMC Cancer 10, 478 (2010).
   PubMed Web of Science ®Google Scholar
• Okada T , KamadaT, TsujiHet al. Carbon ion radiotherapy: clinical experiences at national institute of radiological science (NIRS). J. Radiat. Res. (Tokyo) 51(4), 355–364 (2010).
   PubMed Web of Science ®Google Scholar
• Gruber ML , RazaS, GruberDet al. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity. J. Clin. Oncol. 27, 15 (2009) (Abstract 2017).
   Web of Science ®Google Scholar
• Gilbert MR , WangM, AldapeKet al. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J. Clin. Oncol. 27, 15 (2009) (Abstract 2011).
   Web of Science ®Google Scholar
• Soffietti R , RudàR, TrevisanEet al. Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: a multicenter Italian study. J. Clin. Oncol. 27, 15 (2009) (Abstract 2012).
   Web of Science ®Google Scholar
• Raizer JJ , GrimmS, RiceLet al. A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas. J. Clin. Oncol. 27, 15 (2009) (Abstract 2044).
   Web of Science ®Google Scholar
• Altaha R , AlmubarakM, NewtonMDet al. A pilot study of fosbretabulin with bevacizumab in recurrent high-grade gliomas. J. Clin. Oncol. 28, 15 (2010) (Abstract TPS147).
   PubMedGoogle Scholar
• Bogdahn U , SchneiderT, OliushineVet al. Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints. J. Clin. Oncol. 27, 15 (2009) (Abstract 2037).
   Google Scholar
• Chi AS , GerstnerER, EichlerAFet al. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 27, (2009) (Abstract e13010).
   Web of Science ®Google Scholar
• Brandes AA , StuppR, HauPet al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur. J. Cancer 46(2), 348–354 (2010).
   PubMed Web of Science ®Google Scholar
• Batchelor T , EichlerAF, PlotkinSRet al. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 27, (2009) (Abstract 2035).
   Web of Science ®Google Scholar
• Schiff D , ReardonDA, KesariSet al. Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). J. Clin. Oncol. 28, 15 (2010) (Abstract 2011).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD , ErvinT, FriedmanEet al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15), 3663–3669 (2010).
   PubMed Web of Science ®Google Scholar
• Friedman HS , VredenburghJJ, DesjardinsAet al. A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. J. Clin. Oncol. 27, 15 (2009) (Abstract e13024).
   Web of Science ®Google Scholar
• Neyns B , ChaskisC, DujardinMet al. Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. J. Clin. Oncol. 27, 15 (2009) (Abstract 2038).
   Web of Science ®Google Scholar
• Supko JG , GrossmanSA, PeereboomDMet al. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma. J. Clin. Oncol. 27, 15 (2009) (Abstract 2039).
   Web of Science ®Google Scholar
• Wick W , PuduvalliVK, ChamberlainMCet al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Butowski NA , LambornK, ChangSet al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation therapy in patients with glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27, 15 (2009) (Abstract 2020).
   Web of Science ®Google Scholar
• Sarkaria JN , GalanisE, WuWet al. NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. J. Clin. Oncol. 27, 15 (2009) (Abstract 2019).
   Web of Science ®Google Scholar
• Mason WP , MacNeilM, EasawJet al. A phase I study of temozolomide (TMZ) and RAD001 in patients (pts) with glioblastoma multiforme (GBM). J. Clin. Oncol. 27, 15 (2009) (Abstract 2036).
   Google Scholar
• Fiveash JB , ChowdharySA, PeereboomD. NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM).J. Clin. Oncol.27, 15 (2009) (Abstract 2010).
   Web of Science ®Google Scholar
• Lamar RE , SpigelDR, BurrisHAet al. Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM). J. Clin. Oncol. 27, 15 (2010) (Abstract 2018).
   Google Scholar
• Desjardins A , ReardonDA, GururanganSet al. Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J. Clin. Oncol. 27, (2009) (Abstract e13004).
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P , ChowdharyS, BremSet al. A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma. J. Clin. Oncol. 28, 15 (2010) (Abstract TPS150).
   PubMed Web of Science ®Google Scholar
• Blakeley JO , YeX, GrossmanSAet al. Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma. J. Clin. Oncol. 28, 15 (2010) (Abstract 2012).
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S , DesjardinsA, VredenburghJJet al. Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J. Clin. Oncol. 27, 15 (2009) (Abstract 2045).
   Web of Science ®Google Scholar
• Drappatz J , NordenAD, WongET. Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma.J. Clin. Oncol.27, 15 (2009) (Abstract 2031).
   Web of Science ®Google Scholar
• Herndon J , VredenburghJ, ReardonDet al. Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J. Clin. Oncol. 27, (2009) (Abstract e13016).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick JP , VredenburghJJ, DesjardinsAet al. Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. J. Clin. Oncol. 27, (2009) (Abstract e13007).
   Web of Science ®Google Scholar
• Mcnicol KA , KreislTN, IwamotoFMet al. Phase I/II study of vandetanib for patients with recurrent malignant gliomas. J. Clin. Oncol. 28, 15 (2010) (Abstract 2083).
   PubMedGoogle Scholar
• Hasselbalch B , LassenU, HansenSet al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro. Oncol. 12(5), 508–516 (2010).
   PubMed Web of Science ®Google Scholar
• Chang SM , KuhnJ, LambornKet al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J. Clin. Oncol. 27, 15 (2009) (Abstract 2004).
   Web of Science ®Google Scholar
• Reardon D , DesjardinsA, VredenburghJJet al. Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J. Clin. Oncol. 27, 15 (2009) (Abstract 2046).
   Web of Science ®Google Scholar
• Prados M , GilbertM, KuhnJet al. Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J. Clin. Oncol. 27, 15 (2009) (Abstract 2005).
   Web of Science ®Google Scholar
• Wen PY , CloughesyT, KuhnJet al. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J. Clin. Oncol. 27, 15 (2009) (Abstract 2006).
   Web of Science ®Google Scholar
• De Groot JF , PradosM, UrquhartTet al. A Phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J. Clin. Oncol. 27, 15 (2009) (Abstract 2047).
   Web of Science ®Google Scholar
• Wen PY , PradosM, SchiffDet al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J. Clin. Oncol. 28, 15 (2010) (Abstract 2006).
   PubMedGoogle Scholar
• Frentzas SN , GrovesMD, BarriusoJet al. Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J. Clin. Oncol. 27, 15 (2009) (Abstract 2040).
   Web of Science ®Google Scholar
• Fink K , MikkelsenT, NaborsLBet al. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study. J. Clin. Oncol. 28, 15 (2009) (Abstract 2010).
   PubMed Web of Science ®Google Scholar
• Drappatz J , BrennerAJ, RosenfeldSet al. ANG1005: Results of a phase I study in patients with recurrent malignant glioma. J. Clin. Oncol. 28, 15 (2010) (Abstract 2009).
   PubMedGoogle Scholar
• Benouaich-Amiel A , MazzaE, MassardCet al. Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG). J. Clin. Oncol. 28, 15 (2010) (Abstract 2087).
   PubMed Web of Science ®Google Scholar

Websites

• CFaF American Cancer Society www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
   Google Scholar
• ASCO Annual Meeting 2009 and 2010, CNS Tumors Abstracts Section. www.asco.org
   Google Scholar